チェコ の 国立 銀行 は , 2 億 7,770 万 ドル ( 約 340 億 円 ) 相当 の Vertex 製薬 会社 の 株 を 引き上げ まし た。 The Czech National Bank boosted its Vertex Pharmaceuticals stake to 62,770 shares, worth $27.9 million, as the company posted strong Q2 earnings.

チェコ国立銀行は,ヴェルテックス製薬の株式を3,790株増額し,合計で27,900万ドルの価値の62,770株に増加しました. The Czech National Bank increased its stake in Vertex Pharmaceuticals by 3,790 shares, bringing its total to 62,770 shares valued at $27.9 million. バイオテクノロジー会社は,4.52ドルのEPSで,0.28ドルの見積もりと,2.94億ドルの収益を上回り,同比11.3%の年収で,強力なQ2結果を報告しました. The biotech firm reported strong Q2 results with EPS of $4.52, beating estimates by $0.28, and revenue of $2.94 billion, up 11.3% year-over-year. 株式は,平成50日平均で421.34ドルと,価格対照比で28.11ドルとする. Its stock has a 50-day moving average of $421.34 and a price-to-earnings ratio of 28.11. ヴェラシティ・キャピタルが5.1%の株式を減持し, 戦略アドボケイトズ・LLCは税務技術会社であるVertex, Inc.の565株を買い, 9.6%の株式を増加させた. Veracity Capital reduced its holding by 5.1%, while Strategic Advocates LLC bought 565 shares of Vertex, Inc., a tax technology company, increasing its stake by 9.6%. Vertex, Inc.は,0.14ドルの見積もりから0.15ドルのEPSを報告し,収益は14.6%増加した. Vertex, Inc. reported EPS of $0.15, up from a $0.14 estimate, with 14.6% revenue growth. 分析者は年間0.38ドルのEPSを予想している. Analysts expect $0.38 EPS for the year.